ALDH7A1 and chronic obstructive pulmonary disease: cAMP can suppress key inflammatory responses and is the target of phosphodiesterase (PDE) inhibitors, which represent one of the most significant signaling pathways in COPD and are the target of FDA-approved mediations [38].